Back

The effect of empagliflozin on right ventricular function in heart failure patients with reduced ejection fraction: analysis from the randomized empire hf clinical trial

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Probing deeper into the pathophysiology of heart failure Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Miss Maria Callesen Hansen

Odense University Hospital, Odense (Denmark)

5 More presentations in this session

Presentation thumbnail
Cardiac contractility index, a novel biomarker of incident heart failure amongst people with normal left ventricular ejection fraction in the UK Biobank
Doctor O. Brown (Leeds, GB)
Abstract Slides Video
Presentation thumbnail
Significant correlation between the extent of myocardial fibrosis and heart failure parameters in patients undergoing transcatheter aortic valve implantation.
Doctor K. Yamaguchi (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Genetic and phenotypic architecture of biventricular trabeculation
Doctor K. McGurk (London, GB)
Abstract Slides Video
Presentation thumbnail
Neurodegeneration is highly associated with comorbidity burden in HFrEF patients
Doctor S. Prausmueller (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Exome sequencing in over 63,000 patients in TIMI trials uncovers pathogenic cardiomyopathy variant carriers with high risk for heart failure and cardiovascular death
Doctor S. Kany (Hamburg, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Probing deeper into the pathophysiology of heart failure
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Clinical characteristics and long-term prognosis of patients with heart failure with reduced, mildly reduced, and preserved left ventricular ejection fraction secondary to Chagas cardiomyopathy
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources